Premium
Treatment outcomes and related clinical characteristics in patients with burning mouth syndrome
Author(s) -
Kim MoonJong,
Kim Jihoon,
Kho HongSeop
Publication year - 2021
Publication title -
oral diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.953
H-Index - 87
eISSN - 1601-0825
pISSN - 1354-523X
DOI - 10.1111/odi.13693
Subject(s) - clonazepam , medicine , burning mouth syndrome , gabapentin , depression (economics) , anesthesia , alternative medicine , pathology , economics , macroeconomics
Objectives To evaluate the treatment outcomes of medication therapies in patients with burning mouth syndrome (BMS) and to identify the clinical characteristics that may affect the efficacy of prescribed medications. Methods This is a retrospective study of 769 patients with oral burning sensations. Of these patients, 420 patients diagnosed as the primary BMS received an “Initial Approach” that involved a detailed explanation about its etiopathophysiology, self‐care instruction, and use of an oral lubricant. Neuropathic medications were prescribed for 277 patients who did not respond to the initial approach. Clinical characteristics, prescribed medications, and changes in intensity of oral symptoms were reviewed. Results Clonazepam was administered as the first‐line medication. Alpha‐lipoic acid (ALA), gabapentin, and nortriptyline were commonly administered in combination with clonazepam. More than two‐thirds of the patients reported a marked improvement in oral symptoms after treatments with combination of neuropathic medications and ALA. The efficacies of the initial approach and clonazepam had significant positive associations with the initial intensity of oral symptoms and significant negative associations with depression. Conclusions Clonazepam therapy in combination with appropriate medications was effective for managing patients with BMS. The initial intensity of oral symptoms and psychological status were significantly associated with treatment outcomes.